RegulatoryMay 8, 2026, 04:32 PM
XORTX Therapeutics Estimates Stockholders' Equity at $4.1M, Exceeds Nasdaq Minimum
AI Summary
XORTX Therapeutics Inc. announced that it estimates its stockholders' equity to be approximately $4.1 million as of May 8, 2026. This preliminary, unaudited estimate indicates that the company currently exceeds the Nasdaq Capital Market's minimum stockholders' equity requirement for listing compliance. The estimate considers the company's financial position as of March 31, 2026, the recent acquisition of Vectus Biosystems Limited's VB4-P5 asset, and estimated results for Q1 and Q2 2026.
Key Highlights
- XORTX Therapeutics estimates stockholders' equity at approximately $4.1 million.
- This estimated amount exceeds the Nasdaq Capital Market's minimum listing requirement.
- The estimate considers financial position as of March 31, 2026.
- It also includes the April 13, 2026 acquisition of Vectus Biosystems' VB4-P5 asset.
- The stockholders' equity estimates are preliminary, unaudited, and subject to change.
Price Impact
More from XRTX